Companies Dominating the Preeclampsia Diagnostics Landscape
- ACON Laboratories Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bio Rad Laboratories Inc.
- BioCheck Inc.
- bioMerieux SA
- Cardinal Health Inc.
- Diabetomics Inc.
- F. Hoffmann La Roche Ltd.
- Thermo Fisher Inc.
- Biora Therapeutics Inc
- Sysmex Corporation
- Hitachi Ltd.
- Fujirebio Diagnostics
- Siemens Healthineers AG
- Fujifilm Corporation
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of preeclampsia diagnostics is evaluated at USD 1.42 billion.
Preeclampsia Diagnostics Market size was over USD 1.38 billion in 2024 and is anticipated to exceed USD 2.08 billion by the end of 2037, witnessing over 3.2% CAGR during the forecast period i.e., between 2025-2037. The growing prevalence of pre-termed births, increasing innovative tests development will drive the market growth.
North America industry is expected to hold largest revenue share of 35% by 2037, due to increasing focus on drug delivery services and vaccine discovery and development in the region.
The major players in the market are of Cardinal Health Inc., Diabetomics Inc., F. Hoffmann La Roche Ltd., Thermo Fisher Inc., Biora Therapeutics Inc, and others.
